{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:19:02Z","timestamp":1789593542254,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA33572"],"award-info":[{"award-number":["P30CA33572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008307","name":"Beckman Research Institute, City of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008307","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22\\u20131-0331"],"award-info":[{"award-number":["W81XWH-22\\u20131-0331"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-25\\u20131-0500"],"award-info":[{"award-number":["HT9425-25\\u20131-0500"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bcp.2026.117872","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T15:37:40Z","timestamp":1772984260000},"page":"117872","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Epitranscriptomic signatures of malignancy: how RNA modifications shape breast and ovarian tumor progression"],"prefix":"10.1016","volume":"248","author":[{"given":"Pankaj","family":"Garg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharad S.","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.bcp.2026.117872_b0005","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers13174287","article-title":"Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review","volume":"13","author":"\u0141ukasiewicz","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bcp.2026.117872_b0010","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3390\/diagnostics15040406","article-title":"Early diagnosis of ovarian cancer: a comprehensive review of the advances, challenges, and future directions","volume":"15","author":"Hong","year":"2025","journal-title":"Diagnostics"},{"issue":"4","key":"10.1016\/j.bcp.2026.117872_b0015","doi-asserted-by":"crossref","first-page":"345","DOI":"10.21037\/apm-25-30","article-title":"New progress and challenges of targeted therapies for breast cancer","volume":"14","author":"Wang","year":"2025","journal-title":"Ann. Palliative Med."},{"key":"10.1016\/j.bcp.2026.117872_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1464125","article-title":"Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects","volume":"14","author":"Zhu","year":"2024","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.bcp.2026.117872_b0025","doi-asserted-by":"crossref","first-page":"13851","DOI":"10.3390\/ijms232213851","article-title":"Epitranscriptome: review of top 25 most-studied RNA modifications","volume":"23","author":"Arzumanian","year":"2022","journal-title":"Intl J Mol Sci"},{"key":"10.1016\/j.bcp.2026.117872_b0030","doi-asserted-by":"crossref","unstructured":"Wu, H., Chen, S., Li, X., Li, Y., Shi, H., Qing, Y., Shi, B., Tang, Y., Yan, Z., Hao, Y., Wang, D., & Liu, W. (2025). RNA modifications in cancer. MedComm, 6(1), e70042. doi:10.1002\/mco2.70042.","DOI":"10.1002\/mco2.70042"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0035","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40164-022-00298-7","article-title":"Role of m6A writers, erasers and readers in cancer","volume":"11","author":"Fang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117872_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1458588","article-title":"Mechanisms of tamoxifen resistance: insight from long non-coding RNAs","volume":"14","author":"Yan","year":"2024","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40164-025-00648-1","article-title":"RNA modifications in the tumor microenvironment: insights into the cancer-immunity cycle and beyond","volume":"14","author":"Ding","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117872_b0050","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s12964-023-01385-w","article-title":"The role of m6A epigenetic modifications in tumor coding and non-coding RNA processing","volume":"21","author":"Wen","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bcp.2026.117872_b0055","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2025.1549588","article-title":"The role of m5C, m1A and m7G modifications in tumors of urinary system","volume":"13","author":"Xue","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bcp.2026.117872_b0060","article-title":"Roles and therapeutic implications of m6A modification in cancer immunotherapy","volume":"14","author":"Pan","year":"2023","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.bcp.2026.117872_b0065","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1007\/s00018-020-03466-2","article-title":"Adenosine-to-inosine RNA editing in the immune system: friend or foe?","volume":"77","author":"Nakahama","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0070","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/15476286.2022.2096793","article-title":"Progress and application of epitranscriptomic m6A modification in gastric cancer","volume":"19","author":"Xu","year":"2022","journal-title":"RNA Biol."},{"key":"10.1016\/j.bcp.2026.117872_b0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s10020-024-00965-x","article-title":"N6-methyladenosine and its epitranscriptomic effects on hematopoietic stem cell regulation and leukemogenesis","volume":"30","author":"Chang","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.bcp.2026.117872_b0080","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1038\/s41467-024-48437-4","article-title":"Transfer learning enables identification of multiple types of RNA modifications using nanopore direct RNA sequencing","volume":"15","author":"Wu","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bcp.2026.117872_b0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/21541264.2022.2057177","article-title":"m6A RNA modification in transcription regulation","volume":"12","author":"Akhtar","year":"2021","journal-title":"Transcription"},{"key":"10.1016\/j.bcp.2026.117872_b0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12943-020-01194-6","article-title":"Novel insight into the regulatory roles of diverse RNA modifications: Re-defining the bridge between transcription and translation","volume":"19","author":"Shi","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bcp.2026.117872_b0095","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-024-01777-5","article-title":"RNA modifications in cellular metabolism: implications for metabolism-targeted therapy and immunotherapy","volume":"9","author":"Liu","year":"2024","journal-title":"Sig Transduct Target Ther"},{"issue":"24","key":"10.1016\/j.bcp.2026.117872_b0100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000042857","article-title":"Oncogenic stress response mechanisms as new therapeutic targets in cancer treatment: a review","volume":"104","author":"Iovanna","year":"2025","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0105","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1186\/s12967-024-05771-x","article-title":"N6-Methyladenosine methylation modification in breast cancer: current insights","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-022-01231-5","article-title":"Functions, mechanisms, and therapeutic implications of METTL14 in human cancer","volume":"15","author":"Guan","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2026.117872_b0115","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3389\/fonc.2019.01403","article-title":"Multiple functions and mechanisms underlying the role of METTL3 in human cancers","volume":"9","author":"Zheng","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0120","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13578-024-01293-7","article-title":"Reading the m6A-encoded epitranscriptomic information in development and diseases","volume":"14","author":"Chen","year":"2024","journal-title":"Cell Biosci."},{"issue":"2","key":"10.1016\/j.bcp.2026.117872_b0125","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.gendis.2023.02.054","article-title":"Decoding m6A mRNA methylation by reader proteins in liver diseases","volume":"11","author":"Sun","year":"2023","journal-title":"Genes & Diseases"},{"issue":"16","key":"10.1016\/j.bcp.2026.117872_b0130","doi-asserted-by":"crossref","first-page":"8404","DOI":"10.7150\/thno.112332","article-title":"Epitranscriptomic mechanisms and implications of RNA m5C modification in cancer","volume":"15","author":"Mao","year":"2025","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0135","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13058-024-01847-0","article-title":"NSUN2\/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation","volume":"26","author":"Zhang","year":"2024","journal-title":"Breast Cancer Research: BCR"},{"key":"10.1016\/j.bcp.2026.117872_b0140","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1186\/s12967-024-05687-6","article-title":"Implications of RNA pseudouridylation for cancer biology and therapeutics: a narrative review","volume":"22","author":"Ding","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bcp.2026.117872_b0145","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12964-023-01401-z","article-title":"Research progress of N1-methyladenosine RNA modification in cancer","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s43556-025-00314-2","article-title":"The m6A modification in cancer: roles, implications, and its potential in therapy","volume":"6","author":"Wei","year":"2025","journal-title":"Mol. Biomed."},{"issue":"7","key":"10.1016\/j.bcp.2026.117872_b0155","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/2211-5463.13415","article-title":"Ets family proteins regulate the EMT transcription factors Snail and ZEB in cancer cells","volume":"12","author":"Ichikawa","year":"2022","journal-title":"FEBS Open Bio"},{"issue":"14","key":"10.1016\/j.bcp.2026.117872_b0160","doi-asserted-by":"crossref","first-page":"12024","DOI":"10.1074\/jbc.M110.168625","article-title":"Functional cooperation between Snail1 and twist in the regulation of ZEB1 expression during epithelial to mesenchymal transition","volume":"286","author":"Dave","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.117872_b0165","first-page":"16","article-title":"Epigenetic mechanisms of tamoxifen resistance in luminal breast cancer","volume":"5","author":"Abdel-Hafiz","year":"2017","journal-title":"Diseases (basel, Switzerland)"},{"issue":"9","key":"10.1016\/j.bcp.2026.117872_b0170","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70803","article-title":"Targeting triple-negative breast cancer: resistance mechanisms and therapeutic advancements","volume":"14","author":"Raman","year":"2025","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0175","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s12672-024-01205-8","article-title":"The role of the ALKBH5 RNA demethylase in invasive breast cancer","volume":"15","author":"Woodcock","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bcp.2026.117872_b0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s40364-025-00794-y","article-title":"RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation","volume":"13","author":"Zhao","year":"2025","journal-title":"Biomark Res"},{"issue":"12","key":"10.1016\/j.bcp.2026.117872_b0185","article-title":"Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine","volume":"15","author":"Adhit","year":"2023","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.bcp.2026.117872_b0190","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70388","article-title":"Transforming cancer diagnostics: the emergence of liquid biopsy and epigenetic markers","volume":"6","author":"Saha","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.bcp.2026.117872_b0195","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1186\/s12935-021-02318-8","article-title":"RNA m6A methylation regulators in ovarian cancer","volume":"21","author":"Guo","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.117872_b0200","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s12935-020-01445-y","article-title":"Reshaping the role of m6A modification in cancer transcriptome: a review","volume":"20","author":"Yang","year":"2020","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","article-title":"The role of m6A RNA methylation in cancer metabolism","volume":"21","author":"An","year":"2022","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0210","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13578-024-01286-6","article-title":"Insights into the m6A demethylases FTO and ALKBH5: structural, biological function, and inhibitor development","volume":"14","author":"Gao","year":"2024","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43556-023-00139-x","article-title":"RNA modification: mechanisms and therapeutic targets","volume":"4","author":"Qiu","year":"2023","journal-title":"Mol. Biomed."},{"issue":"7","key":"10.1016\/j.bcp.2026.117872_b0220","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.3390\/curroncol31070283","article-title":"The complex tumor microenvironment in ovarian cancer: therapeutic challenges and opportunities","volume":"31","author":"Garlisi","year":"2024","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117872_b0225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012744","article-title":"m6A-driven transcriptomic rewiring in tumor immune surveillance","volume":"13","author":"Malvi","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"12","key":"10.1016\/j.bcp.2026.117872_b0230","first-page":"5782","article-title":"Cancer stem cells: a major culprit of intra-tumor heterogeneity","volume":"11","author":"Naz","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117872_b0235","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241247170","article-title":"The role of m6A-mediated DNA damage repair in tumor development and chemoradiotherapy resistance","volume":"31","author":"Qu","year":"2024","journal-title":"Cancer Control: J. Moffitt Cancer Center"},{"issue":"6","key":"10.1016\/j.bcp.2026.117872_b0240","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185149","article-title":"KRAS mutants confer platinum resistance by regulating ALKBH5 posttranslational modifications in lung cancer","volume":"135","author":"Yu","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"23","key":"10.1016\/j.bcp.2026.117872_b0245","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1158\/0008-5472.CAN-24-1102","article-title":"MYC drives mRNA pseudouridylation to mitigate proliferation-induced cellular stress during cancer development","volume":"84","author":"Ding","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.117872_b0250","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12943-020-01263-w","article-title":"The role of m6A, m5C and \u03a8 RNA modifications in cancer: Novel therapeutic opportunities","volume":"20","author":"Nombela","year":"2021","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0255","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s10565-024-09924-y","article-title":"RNA modification regulators as promising biomarkers in gynecological cancers","volume":"40","author":"Qi","year":"2024","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.bcp.2026.117872_b0260","first-page":"77","article-title":"Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes","volume":"205","author":"Giannopoulou","year":"2019","journal-title":"Transl. Res. J. Labor. Clin. Med."},{"issue":"9","key":"10.1016\/j.bcp.2026.117872_b0265","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41591-024-03142-z","article-title":"Proteomic signatures improve risk prediction for common and rare diseases","volume":"30","author":"Carrasco-Zanini","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bcp.2026.117872_b0270","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1186\/s12964-024-01854-w","article-title":"Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance","volume":"22","author":"Tang","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12275-022-00005-5","article-title":"Recent advances in CRISPR-Cas technologies for synthetic biology","volume":"61","author":"Jeong","year":"2023","journal-title":"J. Microbiol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117872_b0280","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.7150\/jca.60381","article-title":"The m6A RNA methyltransferase METTL3\/METTL14 promotes leukemogenesis through the mdm2\/p53 pathway in acute myeloid leukemia","volume":"13","author":"Sang","year":"2022","journal-title":"J. Cancer"},{"key":"10.1016\/j.bcp.2026.117872_b0285","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12964-023-01360-5","article-title":"New insights into the regulation of METTL3 and its role in tumors","volume":"21","author":"Jin","year":"2023","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0290","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41421-023-00604-5","article-title":"WTAP-VIRMA counteracts dsDNA binding of the m6A writer METTL3-METTL14 complex and maintains N6-adenosine methylation activity","volume":"9","author":"Yan","year":"2023","journal-title":"Cell Discovery"},{"issue":"3","key":"10.1016\/j.bcp.2026.117872_b0295","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/curroncol32030159","article-title":"Targeting m6A RNA modification in tumor therapeutics","volume":"32","author":"Mao","year":"2025","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.bcp.2026.117872_b0300","first-page":"4179","article-title":"Hypoxia-induced m6A demethylase ALKBH5 promotes ovarian cancer tumorigenicity by decreasing methylation of the lncRNA RMRP","volume":"13","author":"Lyu","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.bcp.2026.117872_b0305","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1145766","article-title":"Epitranscriptomics in the development, functions, and disorders of cancer stem cells","volume":"13","author":"Hao","year":"2023","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0310","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcaf006","article-title":"The IGF2BP1 oncogene is a druggable m6A-dependent enhancer of YAP1-driven gene expression in ovarian cancer","volume":"7","author":"Schott","year":"2025","journal-title":"NAR Cancer"},{"issue":"17","key":"10.1016\/j.bcp.2026.117872_b0315","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.bcp.2026.117872_b0320","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3390\/polym17081010","article-title":"Development of stimuli-responsive polymeric nanomedicines in hypoxic tumors and their therapeutic promise in oral cancer","volume":"17","author":"Hou","year":"2025","journal-title":"Polymers"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0325","article-title":"Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: a comprehensive overview. Biochimica et biophysica acta","volume":"1880","author":"Garg","year":"2025","journal-title":"Reviews on Cancer"},{"issue":"5","key":"10.1016\/j.bcp.2026.117872_b0330","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.cell.2017.09.049","article-title":"Synthetic RNA-based immunomodulatory gene circuits for cancer immunotherapy","volume":"171","author":"Nissim","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2026.117872_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discovery"},{"issue":"5","key":"10.1016\/j.bcp.2026.117872_b0340","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/biomedicines9050500","article-title":"Paclitaxel-based chemotherapy targeting cancer stem cells from mono- to combination therapy","volume":"9","author":"Nawara","year":"2021","journal-title":"Biomedicines"},{"issue":"7","key":"10.1016\/j.bcp.2026.117872_b0345","doi-asserted-by":"crossref","first-page":"e6989","DOI":"10.1002\/cam4.6989","article-title":"Targeting RNA modifications with pharmacological agents: New frontiers in cancer therapy","volume":"13","author":"Guan","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.bcp.2026.117872_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1706557","article-title":"Epitranscriptomic control of cancer immunity and therapy resistance","volume":"16","author":"Zhao","year":"2025","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.117872_b0355","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcab036","article-title":"Regulatory roles of RNA modifications in breast cancer","volume":"3","author":"Kumari","year":"2021","journal-title":"NAR Cancer"},{"key":"10.1016\/j.bcp.2026.117872_b0360","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1016\/j.csbj.2021.09.025","article-title":"Machine learning applications in RNA modification sites prediction","volume":"19","author":"El Allali","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0365","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12935-025-03651-y","article-title":"Integrative machine learning model of RNA modifications predict prognosis and treatment response in patients with breast cancer","volume":"25","author":"Wang","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"11","key":"10.1016\/j.bcp.2026.117872_b0370","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/biology13110848","article-title":"Integrating molecular perspectives: strategies for comprehensive multi-omics integrative data analysis and machine learning applications in transcriptomics, proteomics, and metabolomics","volume":"13","author":"Sanches","year":"2024","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.bcp.2026.117872_b0375","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.tig.2021.06.014","article-title":"Crosstalk between epitranscriptomic and epigenetic mechanisms in gene regulation","volume":"38","author":"Kan","year":"2022","journal-title":"Trends Genetics: TIG"},{"issue":"4","key":"10.1016\/j.bcp.2026.117872_b0380","article-title":"Integrated analysis of transcriptional and metabolic responses to mitochondrial stress","volume":"5","author":"Kelley","year":"2025","journal-title":"Cell Rep. Methods"},{"issue":"3","key":"10.1016\/j.bcp.2026.117872_b0385","doi-asserted-by":"crossref","DOI":"10.1002\/qub2.70002","article-title":"Revolutionizing multi\u2010omics analysis with artificial intelligence and data processing","volume":"13","author":"Yetgin","year":"2025","journal-title":"Quant. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0390","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41065-025-00630-1","article-title":"A combined transcriptomic, epigenetic, and functional analysis identifies novel biomarkers in breast cancer","volume":"163","author":"Gari","year":"2025","journal-title":"Hereditas"},{"key":"10.1016\/j.bcp.2026.117872_b0395","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12967-023-03960-8","article-title":"Liquid biopsies: the future of cancer early detection","volume":"21","author":"Connal","year":"2023","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.bcp.2026.117872_b0400","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges","volume":"5","author":"Li","year":"2024","journal-title":"MedComm"},{"issue":"4","key":"10.1016\/j.bcp.2026.117872_b0405","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf361","article-title":"Research on RNA modification in disease diagnosis and prognostic biomarkers: current status and challenges","volume":"26","author":"Shi","year":"2025","journal-title":"Brief. Bioinform."},{"issue":"8","key":"10.1016\/j.bcp.2026.117872_b0410","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1002\/ijc.35523","article-title":"A promising frontier of circulating messenger RNA in liquid biopsy: from mechanisms to clinical applications","volume":"157","author":"Li","year":"2025","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0415","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ymthe.2021.12.008","article-title":"RNA epitranscriptomics: a promising new avenue for cancer therapy","volume":"30","author":"Yang","year":"2022","journal-title":"Mol. Ther. J. Am. Soc. Gene Therapy"},{"key":"10.1016\/j.bcp.2026.117872_b0420","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1186\/s12935-021-02371-3","article-title":"Emerging role of m6A methylation modification in ovarian cancer","volume":"21","author":"Chang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bcp.2026.117872_b0425","doi-asserted-by":"crossref","DOI":"10.1177\/10732748251342685","article-title":"M6A methylation regulators METTL3 and ALKBH5 are risk factors for EGFR-mutant NSCLC","volume":"32","author":"Zhi","year":"2025","journal-title":"Cancer Control: J. Moffitt Cancer Center"},{"issue":"2","key":"10.1016\/j.bcp.2026.117872_b0430","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.tips.2021.10.012","article-title":"CRISPR-based therapeutics: current challenges and future applications","volume":"43","author":"Modell","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"issue":"11","key":"10.1016\/j.bcp.2026.117872_b0435","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1080\/15476286.2020.1722449","article-title":"RNA modifications and cancer","volume":"17","author":"Haruehanroengra","year":"2020","journal-title":"RNA Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.117872_b0440","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-024-02089-6","article-title":"Writers, readers, and erasers RNA modifications and drug resistance in cancer","volume":"23","author":"Chen","year":"2024","journal-title":"Mol. Cancer"},{"issue":"13","key":"10.1016\/j.bcp.2026.117872_b0445","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3390\/cancers16132448","article-title":"Integrating omics data and AI for cancer diagnosis and prognosis","volume":"16","author":"Ozaki","year":"2024","journal-title":"Cancers"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226002042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:42:30Z","timestamp":1778640150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226002042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":89,"alternative-id":["S0006295226002042"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117872","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epitranscriptomic signatures of malignancy: how RNA modifications shape breast and ovarian tumor progression","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.117872","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117872"}}